本文へジャンプ

研究者情報

データ更新日:2020年04月10日

矢野 聖二 (やの せいじ) 教授 YANO Seiji

メール 研究室ウェブサイト

所属組織・役職等


附属病院 副院長(研究担当)
WPIナノ生命科学研究所 主任研究者
がん進展制御研究所 副所長

教育分野

【大学院前期課程】
医薬保健学総合研究科 医科学専攻
【大学院後期課程】
医薬保健学総合研究科 薬学専攻

所属研究室等

腫瘍内科研究分野 TEL:076-265-2794 FAX:076-234-4524

学歴

【出身大学院】
徳島大学 博士課程 医学研究科 1995/03 修了
【出身大学】
徳島大学 医学部 医学科 1990/03 卒業
【取得学位】
博士(医学)

職歴

1997-2000 徳島大学医学部 分子制御内科 助手(1997/01/01-2000/09/30)
2000-2007 徳島大学医学部・歯学部附属病院 講師(2000/10-)
金沢大学 がん進展制御研究所(2007/04/01-)

生年月

1965年09月

所属学会

日本癌学会 評議員(2007-)
日本臨床腫瘍学会 評議員(2007-)
日本呼吸器学会
日本がん転移学会 理事
日本内科学会
日本肺癌学会
日本癌治療学会
日本呼吸器内視鏡学会
米国癌学会
米国臨床腫瘍学会

学内委員会委員等

受賞学術賞

○日本がん転移研究会 研究奨励賞(1998/10)
○徳島大学医学部研究奨励賞(1998/09)
○かなえ医薬振興財団研究助成金(2000/10)
○日本癌学会奨励賞(2005/09)
○三共生命科学研究振興財団研究助成金(2006/01)
○三谷研究開発支援財団研究助成金(2008/07)
○小林がん学術振興会研究助成金(2009/06)
○日本肺癌学会 篠井・河合賞(2010/11/04)
○JCA Mauvernay Award (Applied)(2013/10/05)
○鶴尾隆賞(2014/06/26)
○高松宮妃癌研究基金(2017/02/22)
○金沢大学功労表彰(2017/03/17)

専門分野

呼吸器内科学

専門分野キーワード

がん薬物療法、肺癌転移、分子標的治療、薬剤耐性

研究課題

胸膜中皮腫に対する分子標的治療

肺癌多臓器転移の分子機構解明

分子標的薬の耐性機構の解析

著書

論文

  • Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. Adachi Y, Yanagimura N, Suzuki C, Ootani S, Tanimoto A, Nishiyama A, Yamashita K, Ohtsubo K, Takeuchi S, Yano S. BMC Cancer 2020 査読有 研究論文(学術雑誌)
  • ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer. Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. Clin Cancer Res 2020 査読有 研究論文(学術雑誌)
  • Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer. Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S. J Thorac Oncol 2020 査読有 研究論文(学術雑誌)
  • Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer. Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S. Cancer Sci 111巻 561-570頁 2020 査読有 研究論文(学術雑誌)
  • EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, Nishiyama A, Arai S, Yano S, Wang W. Mol Cancer 18巻 165頁 2019 査読有 研究論文(学術雑誌)

全て表示

  • Analyses of aberrant methylation of tumor suppressive miRNAs in bile in patients with pancreaticobiliary diseases. Ohtsubo K, Miyake K, Arai S, Fukuda K, Yanagimura N, Suzuki C, Otani S, Adachi Y, Tanimoto A, Nishiyama A, Yamashita K, Takeuchi S, Notohara K, Yoshimura K, Yano S. Anticancer Res. 39巻 5449-5459頁 2019 査読有 研究論文(学術雑誌)
  • Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance. Kita K, Fukuda K, Takahashi H, Tanimoto A, Nishiyama A, Arai S, Takeuchi S, Yamashita K, Ohtsubo K, Otani S, Yanagimura N, Suzuki C, Ikeda H, Tamura M, Matsumoto I, Yano S.  Cancer Sci 110巻 3215-3224頁 2019 査読有 研究論文(学術雑誌)
  • Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer. Staub Y, Nishiyama A, Suga Y, Fujita M, Matsushita R, Yano S. Anticancer Res 39巻 3871-3878頁 2019 査読有 研究論文(学術雑誌)
  • Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).  Kimura T, Kawaguchi T, Chiba Y, Yoshioka H, Watanabe K, Kijima T, Kogure Y, Oguri T, Yoshimura N, Niwa T, Kasai T, Hayashi H, Ono A, Asai K, Tanaka H, Yano S, Yamamoto N, Nakanishi Y, Nakagawa K. Jpn J Clin Oncol. 2019 査読有 研究論文(学術雑誌)
  • Distinct localization of mature HGF from its precursor form in developing and repairing stomach. Jangphattananont N, Sato H, Imamura R, Sakai K, Terakado Y, Murakami K, Barker N, Oshima H, Oshima M, Takagi J, Kato Y, Yano S, Matsumoto K. Int J Mol Sci. 20巻 2019 査読有 研究論文(学術雑誌)
  • Caput medusae-like venous dilatations in lung cancer. Adachi Y, Yano S. Internal Med. 2019 査読有 研究論文(学術雑誌)
  • Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor. Sakai K, Passioura T, Sato H, Ito K, Furuhashi H, Umitsu M, Takagi J, Kato Y, Mukai H, Warashina S, Zouda M, Watanabe Y, Yano S, Shibata M, Suga H, Matsumoto K. Nat Chem Biol 15巻 598-606頁 2019 査読有 研究論文(学術雑誌)
  • Distribution and efficacy of lenvatinib in brain metastasis of human anaplastic thyroid cancer cells in severe combined immune-deficient mice. Wang R, Yamada T, Arai S, Fukuda K, Taniguchi H, Tanimoto A, Nishiyama A, Takeuchi S, Yamashita K, Ohtsubo K, Matsui J, Onoda N, Hirata E, Taira S, Yano S. Mol Cancer Ther 18巻 947-956頁 2019 査読有 研究論文(学術雑誌)
  • Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.  Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Tanagitani N, Nishio K, Yano S.  Cancer Res 79巻 1658-1670頁 2019 査読有 研究論文(学術雑誌)
  • AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.  Nat Commun 10巻 259頁 2019 査読有 研究論文(学術雑誌)
  • Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report.  Tanimoto A, Takeuchi S, Kotani H, Yamashita K, Tamada T, Ohtsubo K, Ebi H, Ikeda H, Yano S. BMC Pulmonary Medicine 18巻 193頁 2018 査読有 研究論文(学術雑誌)
  • A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib. Kitade H, Ohtsubo K, Hokkoku K, Mori M, Osamura RY, Sakuma H, Nakai M, Yano S. Int. Cancer Conference J. 8巻 24-28頁 2018 査読有 研究論文(学術雑誌)
  • Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. Nishimura T, Nakata A, Xiaoxi C, Nishi K, Meguro-Horike M, Sasaki S, Kita K, Horike S, Saitoh K, Kato K, Igarashi K, Murayama T, Kohno S, Takahashi C, Mukaida N, Yano S, Soga T, Tojo A, Gotoh N. Oncogene 2018 査読有 研究論文(学術雑誌)
  • Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP. Nat Commun 9巻 3198頁 2018 査読有 研究論文(学術雑誌)
  • Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model. Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S. Clin Cancer Res 24巻 2357-2369頁 2018 査読有 研究論文(学術雑誌)
  • Histone deacetylase inhibition enhances the antitumor activity of a MEK inhibitor in lung cancer cells harboring RAS mutations. Yamada T, Amann JM, Tanimoto A, Taniguchi H, Shukuya T, Timmers C, Yano S, Shilo K, Carbone DP. Mol Cancer Ther 17巻 17-25頁 2018 査読有 研究論文(学術雑誌)
  • In vivo imaging xenograft models for the evaluation of anti-brain-tumor efficacy of targeted drugs. Kita K, Arai S, Nishiyama A, Taniguchi H, Fukuda K, Wang R, Yamada T, Takeuchi S, Tange S, Tajima A, Nakada M, Yasumoto K, Motoo Y, Murakami T, Yano S.  Cancer Med 6巻 2972-2983頁 2018 査読有 研究論文(学術雑誌)
  • Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H.  Oncogene 37巻 1775-1787頁 2018 査読有 研究論文(学術雑誌)
  • Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.  Adachi Y, Watanabe K, Kita K, Kitai H, Kotani H, Sato Y, Inase N, Yano S, Ebi H Carcinogenesis  38巻 1063-1072頁 2017 査読有 研究論文(学術雑誌)
  • Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study). Izumi K, Shigehara K, Nohara T, Narimoto K, Kadono Y, Nanjo S, Yamada T, Ohtsubo K, Yano S, Mizokami A. J Med Invest 64巻 202-204頁 2017 査読有 研究論文(学術雑誌)
  • Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. Taniguchi H, Yamada T, Takeuchi S, Arai S, Fukuda K, Sakamoto S, Kawada M, Yamaguchi H, Mukae H, Yano S. Cancer Sci 108巻 1378-1385頁 2017 査読有 研究論文(学術雑誌)
  • Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. Takeuchi S, Fukuda K, Yamada T, Arai S, Takagi S, Ishii G, Ochiai A, Iwakiri S, Itoi K, Uehara H, Nishihara H, Fujita N, Yano S. Cancer Sci 108巻 1378-1385頁 2017 査読有 研究論文(学術雑誌)
  • A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. Oncotarget 8巻 41474-86頁 2017 査読有 研究論文(学術雑誌)
  • The case of double primary lung adenocarcinomas with an EGFR mutation and ALK translocation successfully treated with alectinib at the post-surgical recurrence. Tsunezuka Y, Tanaka N, Fujimori H, Togashi Y, Baba S, Takeuchi K, Katayanagi K, Kurumaya H, Kitade H, Atagi S, Yano S. J Med Invest 64巻 305-307頁 2017 査読有 研究論文(学術雑誌)
  • In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. Arai S, Kita K, Tanimoto A, Takeuchi T, Fukuda K, Sato H, Yano S. Oncotarget 8巻 73766-7頁 2017 査読有 研究論文(学術雑誌)
  • Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, Hasegawa Y, Satouchi M, Kiura K, Seto T, Yano S. J Med Invest 65巻 317-320頁 2017 査読有 研究論文(学術雑誌)
  • Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol. Takeuchi S, Yoshimura K, Fujiwara T, Ando M, Shimizu S, Nagase K, Hasegawa Y, Takahashi T, Katakami N, Inoue A, Yano S. J Med Invest 64巻 321-325頁 2017 査読有 研究論文(学術雑誌)
  • MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer. Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, Hata A, Katakami N, Okada Y, Yano S. Mol Cancer Ther 16巻 506-515頁 2017 査読有 研究論文(学術雑誌)
  • Amphiregulin triggered EGFR activation confers crizotinib-resistance in a mouse model with EML4-ALK cancer and its circumvention with EGFR inhibitors. Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Yamada T, Yamaguchi H, Mukae H, Yano S. Cancer Sci 108巻 53-60頁 2017 査読有 研究論文(学術雑誌)
  • Antitumor vascular strategy for controlling experimental metastatic spread of human small cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficiency mice. CLINICAL CANCER RESEARCH 11巻 24号 8789-8798頁 2005/12 査読有 原著論文
  • Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an anti-osteoclastic activity. CLINICAL CANCER RESEARCH 11巻 24号 8822-8828頁 2005/12 査読有 原著論文
  • A novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. CANCER SCIENCE 97巻 3号 183-191頁 2006/05 査読有 原著論文
  • Restored expression of MYO18B gene suppresses orthotopic growth and production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice. ONCOLOGY RESEARCH 16巻 5号 235-243頁 2006/10 査読有 原著論文
  • Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions. JOURNAL OF MEDICAL INVESTIGATION 54巻 1号 146-153頁 2007/02 査読有 原著論文
  • Autofluorescence bronchoscopy, a novel modality for the early detection of bronchial premalignant and malignant lesions. JOURNAL OF MEDICAL INVESTIGATION 54巻 261-266頁 2007 査読有
  • The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in SCID mice. CLINICAL CANCER RESEARCH 13巻 5918-5925頁 2007 査読有
  • Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations.  Cancer Research 68巻 9479-9487頁 2008 査読有
  • Lysophosphoatidic acid stimulated proliferation and motility of malignant pleural mesothelioma cells through LPA receptors, LPA1 and LPA2. Cancer Science 99巻 1603-1610頁 2008 査読有
  • Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in NK cell-depleted SCID mice.  CLINICAL CANCER RESEARCH 14巻 660-667頁 2008 査読有
  • E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. CLINICAL CANCER RESEARCH 15巻 7229-7237頁 2009 査読有
  • Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy.  Internal Medicine 48巻 1651-1656頁 2009 査読有
  • Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a case with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. International Journal of Clinical Oncology 14巻 468-472頁 2009 査読有
  • Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. CLINICAL CANCER RESEARCH 15巻 6630-6638頁 2009 査読有
  • A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. Oncology Research 17巻 581-591頁 2009 査読有
  • Intensification therapy of anti-parathyroid hormone-related protein antibody combined with zoledronic acid for bone metastasis of small cell lung cancer cells in severe combined immunodeficient mice. Molecular Cancer Therapeutics 8巻 119-126頁 2009 査読有
  • The role of percutaneous needle biopsy in differentiation of renal tumors.  Japanese Journal of Clinical Oncology 40巻 1081-1086頁 2010 査読有
  • Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan.  The Journal of Medical Investigation 57巻 326-333頁 2010 査読有
  • Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. International Journal of Clinical Oncology 15巻 638-641頁 2010 査読有
  • Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice. Clinical and Experimental Metastasis 27巻 351-359頁 2010 査読有
  • Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. CLINICAL CANCER RESEARCH 16巻 174-183頁 2010 査読有
  • Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2 expressing small cell lung cancer.  CANCER SCIENCE 102巻 2157-2163頁 2011 査読有
  • Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.  Journal of Thoracic Oncology 6巻 2011-2017頁 2011 査読有
  • Pleural mesothelioma instigates tumor associated fibroblasts to promote progression via malignant cytokine network.  American Journal of Pathology 179巻 1483-1493頁 2011 査読有
  • E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.  Molecular Cancer Therapeutics 10巻 1218-1228頁 2011 査読有
  • A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncology Letter 2巻 465-470頁 2011 査読有
  • Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts. British Journal of Cancer 104巻 505-513頁 2011 査読有
  • Reaction of plasma hepatocyte growth factor level in lung cancer patients treated with EGFR-TKIs. International Journal of Cancer 126巻 1410-1416頁 2011 査読有
  • Epithelioid glioblastoma changed to typical glioblastoma -the methylation status of MGMT promoter and 5-ALA fluorescence -. Brain Tumor Pathology 28巻 59-64頁 2011 査読有
  • Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. International Journal of Oncology 41巻 1610-1618頁 2012 査読有
  • Endoscopic findings of upper gastrointestinal lesions in patients with pancreatic cancer. JOURNAL OF ONCOLOGY PRACTICE 13巻 420-426頁 2012 査読有
  • Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor to overcome erlotinib resistance in EGFR mutant lung cancer. Molecular Cancer Therapeutics 11巻 2149-2157頁 2012 査読有
  • Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. American Journal of Pathology 181巻 1034-1043頁 2012 査読有
  • Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. CLINICAL CANCER RESEARCH 18巻 3592-3602頁 2012 査読有
  • Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis. Journal of Thoracic Oncology 7巻 1078-1085頁 2012 査読有
  • E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. CLINICAL CANCER RESEARCH 18巻 1663-1671頁 2012
  • Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.  Journal of Thoracic Oncology 7巻 272-280頁 2012 査読有
  • A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. The Journal of Immunology 190巻 6239-6249頁 2013 査読有
  • Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. JOURNAL OF ONCOLOGY PRACTICE 14巻 515-520頁 2013 査読有
  • PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.  Proceedings of the National Academy of Sciences USA 110巻 21124-21129頁 2013 査読有
  • Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLOS ONE 8巻 12号 84700頁 2013 査読有
  • Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. CANCER SCIENCE 104巻 1640-1646頁 2013 査読有
  • KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Cell Cycle 12巻 2100-2112頁 2013 査読有
  • mTOR inhibitors control erlotinib-resistance of EGFR mutant lung cancer cells triggered by HGF. PLOS ONE 8巻 5号 62104頁 2013 査読有
  • EGFR-TKI resistance due to BIM polymorphism can be circumvented by in combination with HDAC inhibition. Cancer Research 73巻 2428-2434頁 2013 査読有
  • Surfactant protein a suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. American Journal of Pathology 182巻 1843-1853頁 2013 査読有
  • Novel PI3K-mTOR inhibitor, BEZ235, circumvents erlotinib-resistance of EGFR mutant lung cancer cells triggering by HGF. International Journal of Cancer 113巻 505-513頁 2013 査読有
  • Scaffold Aki1, a novel therapeutic target for lung cancer with epidermal growth factor receptor mutations. Oncogene 32巻 4427-4435頁 2013 査読有
  • Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget 5巻 4920-4928頁 2014 査読有
  • Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. Oncology Reports 32巻 1109-1115頁 2014 査読有
  • TAS-115, a novel inhibitor of VEGFR-2 and Met, combined with erlotinib prevented re-growth of HGF-triggered erlotinib resistant lung cancer harboring EGFR mutation. Journal of Thoracic Oncology 9巻 775-783頁 2014 査読有
  • Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nature Communications 6巻 8792頁 2015 査読有
  • Akt kinase-interacting protein1 signals through CREB to drive diffuse malignant mesothelioma. Cancer Research 75巻 4188-4197頁 2015 査読有
  • Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Scientific Reports 5巻 13076頁 2015 査読有
  • Crucial roles of RSK in cell motility by catalyzing serine phosphorylation of EphA2. Nature Communications 6巻 7679頁 2015 査読有
  • LPP inhibits collective cell migration during lung cancer dissemination. Oncogene 35巻 952-964頁 2015 査読有
  • In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.  CANCER SCIENCE 106巻 244-252頁 2015 査読有
  • Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. Journal of Thoracic Oncology 10巻 59-66頁 2015 査読有
  • Amphiregulin triggered EGFR activation confers crizotinib-resistance in a mouse model with EML4-ALK cancer and its circumvention with EGFR inhibitors. CANCER SCIENCE 2016 査読有
  • Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. Molecular and Clinical Oncology 4巻 4号 537-540頁 2016 査読有
  • Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer. Journal of Pharmaceutical Health Care and Sciences 2巻 15頁 2016 査読有
  • Proteolytic inactivation of anti-angiogenic vasohibin-1 by cancer cells. J Biochem 160巻 227-232頁 2016 査読有
  • Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer.  Cancer Discovery 7巻 754-769頁 2016 査読有
  • TMPRSS4 Expression as a Marker of Recurrence in Patients with Lung Cancer. Anticancer Research 36巻 121-127頁 2016 査読有
  • Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Oncogene 35巻 3587-3597頁 2016 査読有
  • High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget 7巻 3847-3856頁 2016 査読有
  • Hsp90 inhibition combined with zoledronic acid controls multiple organ metastases of chemotherapy-refractory small cell lung cancer cells. International Journal of Cancer 138巻 1281-1289頁 2016
  • Antiangiogenic therapies for malignant pleural mesothelioma Yano, Seiji;Li, Qi;Wang, Wei;Yamada, Tadaaki;Takeuchi, Shinji;Nakataki, Emiko;Ogino, Hirokazu;Goto, Hisatsugu;Nishioka, Yasuhiko;Sone, Saburo FRONTIERS IN BIOSCIENCE-LANDMARK 16巻 0号 740-748頁 2011
  • Prognostic Value of Aquired Resistance-related Molecules in Japanese Patients with NSCLC Treated with an EGFR-TKI Uramoto, Hidetaka;Yamada, Tadaaki;Yano, Seiji;Kondo, Nobuyuki;Hasegawa, Seiki;Tanaka, Fumihiro ANTICANCER RESEARCH 32巻 9号 3785-3790頁 2012
  • HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Yano, Seiji;Wang, Wei;Li, Qi;Yamada, Tadaaki;Takeuchi, Shinji;Matsumoto, Kunio;Nishioka, Yasuhiko;Sone, Saburo CURRENT SIGNAL TRANSDUCTION THERAPY 6巻 2号 228-233頁 2011
  • Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Donev, Ivan S.;Wang, Wei;Yamada, Tadaaki;Li, Qi;Takeuchi, Shinji;Matsumoto, Kunio;Yamori, Takao;Nishioka, Yasuhiko;Sone, Saburo;Yano, Seiji CLINICAL CANCER RESEARCH 17巻 8号 2260-2269頁 2011
  • Molecular targeted therapy in metastatic melanoma and thyroid cancer Japanese Journal of Chest Diseases 73巻 2号 180-190頁 2014/02/01 
  • Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. 265(1)巻 55-66頁 2008/01 原著論文
  • The therapeutic efficacy of a autofluorescence bronchoscopy, a novel modality for the early detection of bronchial premalignant and malignant lesions. Hanibuchi M, Yano S, Nishioka Y, Miyoshi T, Kondo K, Uehara H, Sone S. 54巻 3号 261-266頁 2007/08 査読有 原著論文
  • Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma CANCER SCIENCE 106巻 1号 102-107頁 2015/01/01 
  • PI3K INHIBITORS, PI-103, GDC-0941, AND BEZ235, OVERCOME HGFMEDIATED RESISTANCE TO EGFR-TKIS IN EGFR MUTANT LUNG CANCER Yano, Seiji;Donev, Ivan S.;Yamada, Tadaaki;Takeuchi, Shinji;Matsumoto, Kunio JOURNAL OF THORACIC ONCOLOGY 6巻 6号 S575-S576頁 2011
  • The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer Yasumoto, Kazuo;Yamada, Tadaaki;Kawashima, Atsuhiro;Wang, Wei;Li, Qi;Donev, Ivan Shterev;Tacheuchi, Shinji;Mouri, Hisatsugu;Yamashita, Kaname;Ohtsubo, Koushiro;Yano, Seiji CLINICAL CANCER RESEARCH 17巻 11号 3619-3630頁 2011
  • Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations Journal of Thoracic Oncology 2014/11/07 
  • Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma Cancer Science 2014/01/01 
  • Expression of Akt Kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer Pancreas 43巻 7号 1093-1100頁 2014/01/01 
  • [A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan]. Gan to kagaku ryoho. Cancer & chemotherapy 39巻 9号 1427-1430頁 2012/09/01 
  • Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance Respiratory Investigation 52巻 6号 348-356頁 2014/01/01 
  • Distinct allelic expression patterns of imprinted IGF2 in adenocarcinoma and squamous cell carcinoma of the lung Oncology Letters 8巻 6号 2561-2564頁 2014/01/01 

講演・口頭発表等

芸術・フィールドワーク

特許

○RET阻害薬耐性癌に対する治療剤 (公開年月:2016/05/23)
○A925L由来癌細胞株 (公開年月:2015/12/21)

共同研究希望テーマ

○胸膜中皮腫に対する分子標的治療開発
○肺がんの分子標的薬耐性機構の解明と克服

科研費

○基盤研究(C)「胸膜中皮腫に著効を示すVEGF受容体阻害薬の真の標的分子同定と治療への応用」(2007-) 代表者
○基盤研究(B)「HGFによるEGFR活性型変異養成肺癌の分子標的薬耐性を克服する個別化医療開発」(2009-) 代表者
○特定領域研究「肺癌転移の臓器微小環境特性から見た分子標的治療法の開発」(2005-) 分担者
○厚生労働科学研究費補助金 がん政策推進総合研究事業「3学会合同「がんゲノムネット」を用いた,国民への「がんゲノム医療」に関する教育と正しい情報伝達に関する研究」(2018-2020) 分担者
○基盤研究(B)日本学術振興会「分子標的薬で肺がんの根治を目指す治療の非臨床研究基盤の形成」(2019-2021) 代表者
○日本医療研究開発機構 革新的がん医療実用化研究事業「遺伝子スクリーニング基盤(LC-SCRUM-Japan)を利用した,MET遺伝子異常陽性の進行非小細胞肺癌に対する治療開発を目指した研究」(2018-2020) 分担者
○日本医療研究開発機構 次世代がん医療創生研究事業「MAPKシグナル抑制が誘導するフィードバック機構の不均一性解明と制御に基づくKRAS/BRAF変異腫瘍に対する新規治療開発」(2016-2021) 代表者
○日本医療研究開発機構 革新的がん医療実用化研究事業「RET肺がんに対するアレクチニブの医師主導治験と耐性機構解析」(2018-2020) 代表者
○基盤研究(B)「肺がんの髄膜がん腫症における分子標的薬耐性を克服する研究」(2016-2018) 代表者
○基盤研究(B)「肺がんの転移と分子標的薬耐性を克服する統合的研究」(2012-2014) 代表者
○新学術領域研究(研究領域提案型)「呼吸器悪性腫瘍の微小環境の特性を標的とした新規制御法の開発」(2010-2011) 代表者
○基盤研究(B)「HGFによるEGFR活性型変異陽性肺癌の分子標的薬耐性を克服する個別化医療開発」(2009-2011) 代表者

学域・学類担当授業科目

大学院担当授業科目

○内科学概論(2017)
○分子腫瘍学(2017)
○腫瘍内科学特論(2017)
○腫瘍内科学特論(2017)
○腫瘍薬物学特論(2017)
○腫瘍薬物学演習(2017)
○腫瘍薬物学演習(2017)
○腫瘍内科学特論(2017)
○腫瘍薬物学演習(2017)
○腫瘍薬物学特論(2017)
○腫瘍薬物学特論(2017)
○腫瘍薬物学演習(2016)
○腫瘍薬物学演習(2016)
○腫瘍内科学特論(2016)
○腫瘍薬物学特論(2016)
○分子腫瘍学(2016)
○内科学概論(2016)
○腫瘍薬物学特論(2016)
○腫瘍内科学特論(2016)
○腫瘍薬物学演習(2016)
○腫瘍薬物学特論(2016)
○腫瘍内科学特論(2016)
○腫瘍内科学特論(2015)
○腫瘍薬物学特論(2015)
○腫瘍薬物学演習(2015)
○分子腫瘍学(2015)
○分子腫瘍学(2014)
○腫瘍薬物学演習(2014)
○腫瘍内科学特論(2014)
○腫瘍薬物学特論(2014)

他大学の客員教授

○徳島大学
○京都府立医科大学

教育活動(FD)に関する研究

国際事業協力

留学生参加の社会活動

審議会等の参加

講演可能なテーマ

○肺癌の分子標的治療
○胸膜中皮腫の分子標的治療

その他公的社会活動

このページの先頭へ